Oxford BioMedica (LON:OXB) insider Stuart Paynter bought 87,626 shares of the company’s stock in a transaction that occurred on Monday, April 9th. The stock was purchased at an average price of GBX 11 ($0.16) per share, for a total transaction of £9,638.86 ($13,623.83).
LON:OXB opened at GBX 10.96 ($0.15) on Tuesday. Oxford BioMedica has a 52-week low of GBX 4.44 ($0.06) and a 52-week high of GBX 13.19 ($0.19).
Separately, Peel Hunt lifted their target price on shares of Oxford BioMedica from GBX 13 ($0.18) to GBX 16 ($0.23) and gave the stock a “buy” rating in a report on Thursday, March 15th.
ILLEGAL ACTIVITY NOTICE: This report was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/10/oxford-biomedica-oxb-insider-acquires-9638-86-in-stock.html.
About Oxford BioMedica
Oxford BioMedica plc, a biopharmaceutical company, researches, develops, and produces gene and cell therapy products for the treatment of ocular, neurodegenerative, and cancer diseases in Europe and rest of world. The company operates through Partnering and R&D segments. Its LentiVector platform technology integrates genes into non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes.
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.